



## Siklos® (hydroxyurea) – Expanded indication

- On December 7, 2021, the [FDA approved](#) Medunik's [Siklos \(hydroxyurea\)](#), to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
  - Siklos was previously approved for this indication in pediatric patients only.
- The approval of Siklos for the expanded indication was based on ESCORT-HU 1077, in 370 evaluable adult patients who were naïve to hydroxyurea treatment. The incidence and number of vaso-occlusive events, hospitalizations, acute chest syndrome and blood transfusions in the 12-month period before treatment and after initiation of treatment decreased after 12 months of Siklos treatment.
- Siklos carries a boxed warning for myelosuppression and malignancies.
- The most common adverse reactions (> 10%) with Siklos use in adults were infections, headache and dry skin.
- The recommended initial dose of Siklos for treatment of adults with sickle cell anemia is 15 mg/kg once daily based on patient's actual or ideal weight, whichever is less. The dosage can be adjusted based on blood counts and hematologic recovery.
- Refer to the Siklos drug label for complete dosing recommendations in adults and dosing in pediatric patients.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.